FDA Approves Request to Test EZH2 Inhibitor, Tazemetostat, in Mesothelioma Patients
News
The U.S. Food and Drug Administration (FDA) recently accepted an Investigational New Drug (IND) application for tazemetostat as a potential treatment of mesothelioma in adults. The decision allows Epizyme, the company developing tazemetostat, ... Read more